260 Stock Overview A clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Centessa Pharmaceuticals plc Competitors Price History & Performance
Summary of share price highs, lows and changes for Centessa Pharmaceuticals Historical stock prices Current Share Price US$15.60 52 Week High US$16.90 52 Week Low US$5.90 Beta 1.53 1 Month Change -1.89% 3 Month Change 9.86% 1 Year Change 122.86% 3 Year Change 71.43% 5 Year Change n/a Change since IPO -12.36%
Recent News & Updates
Centessa Pharmaceuticals Initiates Phase 2 Trial with ORX750, a Novel Orexin Receptor 2 (OX2R) Agonist Nov 13
CEO & Director recently sold €801k worth of stock Oct 25
Chief Business Officer recently sold €234k worth of stock Sep 30 Centessa Pharmaceuticals plc has filed a Follow-on Equity Offering in the amount of $150 million. Sep 12
Centessa Pharmaceuticals plc Announces Positive Interim Phase 1 Clinical Data with Its Novel Orexin Receptor 2 (OX2R) Agonist, Orx750, in Acutely Sleep-Deprived Healthy Volunteers Sep 10 Centessa Pharmaceuticals plc Announces Chief Financial Officer Changes See more updates
Centessa Pharmaceuticals Initiates Phase 2 Trial with ORX750, a Novel Orexin Receptor 2 (OX2R) Agonist Nov 13
CEO & Director recently sold €801k worth of stock Oct 25
Chief Business Officer recently sold €234k worth of stock Sep 30 Centessa Pharmaceuticals plc has filed a Follow-on Equity Offering in the amount of $150 million. Sep 12
Centessa Pharmaceuticals plc Announces Positive Interim Phase 1 Clinical Data with Its Novel Orexin Receptor 2 (OX2R) Agonist, Orx750, in Acutely Sleep-Deprived Healthy Volunteers Sep 10 Centessa Pharmaceuticals plc Announces Chief Financial Officer Changes
Insufficient new directors Jun 02 Centessa Pharmaceuticals plc has filed a Follow-on Equity Offering in the amount of $100 million. Centessa Pharmaceuticals plc has filed a Follow-on Equity Offering in the amount of $100 million. Apr 24
Centessa Pharmaceuticals plc Announces Open IND for ORX750 Apr 23
New major risk - Revenue and earnings growth Mar 29
New major risk - Revenue and earnings growth Mar 05
Centessa Pharmaceuticals plc Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2A Study of Serpinpc for the Treatment of Hemophilia Dec 11
Centessa Pharmaceuticals plc Announces Dosing of First Subject in Registrational Present-3 Study Evaluating Serpinpc for the Treatment of Hemophilia B with Inhibitors Nov 01
Centessa Pharmaceuticals plc Announces Preclinical Data Supporting Orx750's Potential as A Best-In-Class Oral Ox2r Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders Oct 26
World Sleep Congress Releases an Abstract Submit by Centessa Pharmaceuticals plc Aug 25
New major risk - Revenue and earnings growth Aug 15
Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study Evaluating SerpinPC for the Treatment of Hemophilia B Without Inhibitors Jul 12
New major risk - Share price stability Jul 06
Centessa Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for Serpinpc for Hemophilia B May 23
Centessa Pharmaceuticals Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of LB101, First LockBody® Candidate, for Solid Tumors Jan 27
Centessa Pharmaceuticals plc Announces Additional 18-Months of Continued Treatment Data from Open-Label Extension of Phase 2a Study of SerpinPC for Hemophilia Dec 13
Centessa Pharmaceuticals Announces Karen Anderson as New Chief People Officer Dec 01
High number of new and inexperienced directors Nov 16
The Law Offices of Vincent Wong Announces Class Action Lawsuit Against Centessa Pharmaceuticals plc Nov 15
Centessa Pharmaceuticals plc Announces Departure of Javad Shahidi as Chief Medical Officer Oct 15
Centessa Pharmaceuticals plc Announces Class Action Lawsuit Against Centessa Pharmaceuticals plc Sep 30
Centessa Pharmaceuticals Announces Non-Human Primate Pharmacokinetic and Safety Data for LB101 (PD-L1xCD47) Demonstrating Potential for Enhanced Therapeutic Index Sep 13
Centessa Pharmaceuticals Announces Addition of Harris L. Rotman, Phd, as Senior Vice President of Regulatory Affairs Jul 26
Centessa Pharmaceuticals plc Announces Executive Changes Jul 09
Centessa Pharmaceuticals plc Announces Board Changes Jul 02
Centessa Pharmaceuticals plc Announces Poster Presentation of First Preclinical Data for LockBody Program At 2022 ASCO Annual Meeting Jun 06
Centessa Pharmaceuticals Makes Strategic Decision to Discontinue Clinical Development of Lixivaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD) Jun 03
Centessa Pharmaceuticals plc, Annual General Meeting, Jun 30, 2022 May 24
High number of new and inexperienced directors Apr 27
High number of new and inexperienced directors Apr 05
Centessa Pharmaceuticals Doses First Subject in Global Phase 3 Action Study of Lixivaptan in Autosomal Dominant Polycystic Kidney Disease Feb 25
Centessa Pharmaceuticals Limited Announces Resignation of Robert M. Califf as Member of the Board of Directors Feb 17
Centessa Pharmaceuticals plc Together with Subsidiary Palladio Biosciences, Inc. Initiates Global Phase 3 ACTION Study of Lixivaptan in Autosomal Dominant Polycystic Kidney Disease and Reports Initial Positive Safety Data from ALERT Study Dec 15
Centessa Pharmaceuticals Announces Positive Topline Data from Proof-of-Concept Study of SerpinPC in Severe Hemophilia A and B Patients Not on Prophylaxis Sep 10 Shareholder Returns 260 DE Biotechs DE Market 7D -0.6% 2.3% 0.3% 1Y 122.9% -14.0% 6.9%
See full shareholder returns
Return vs Market: 260 exceeded the German Market which returned 6.9% over the past year.
Price Volatility Is 260's price volatile compared to industry and market? 260 volatility 260 Average Weekly Movement 7.6% Biotechs Industry Average Movement 7.6% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.7% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 260's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 260's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy.
Show more Centessa Pharmaceuticals plc Fundamentals Summary How do Centessa Pharmaceuticals's earnings and revenue compare to its market cap? 260 fundamental statistics Market cap €2.13b Earnings (TTM ) -€155.67m Revenue (TTM ) €6.62m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 260 income statement (TTM ) Revenue US$6.85m Cost of Revenue US$0 Gross Profit US$6.85m Other Expenses US$168.12m Earnings -US$161.26m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -1.22 Gross Margin 100.00% Net Profit Margin -2,353.20% Debt/Equity Ratio 15.2%
How did 260 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/01 14:57 End of Day Share Price 2024/12/30 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Centessa Pharmaceuticals plc is covered by 13 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution null null BMO Capital Markets Equity Research Konstantinos Biliouris BMO Capital Markets Equity Research Mayank Mamtani B. Riley Securities, Inc.
Show 10 more analysts 